Vivesto AB · OMXSTO:VIVE
Vivesto AB — Oasmia Pharmaceutical — SEB Conference 2021
17 slides from Vivesto AB's conference presentation, Jan 19, 2021
Slide 1: SEB Conference
SEB CONFERENCE F.R. Martelet, M.D., CEO 19 January 2021 1
Slide 2: Forward-looking statement
Forward-looking statement IMPORTANT NOTICE The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require p
Slide 3: Oasmia – an innovation-focused specialty pharmaceutical company
Oasmia – an innovation-focused specialty pharmaceutical company XR-17™ technology platform Significant in-/out- Enhances intravenous delivery of established and novel drugs in licensing & M&A opportunities to drive growth diseases including cancer Growing pipeline, focused on Lean and agile Oncology
Slide 4: Building the right team for success
Building the right team for success FRANCOIS MARTELET, FREDRIK JÄRRSTEN* REINHARD KOENIG, M.D. ELIN TRAMPE, M.A. PETER SELIN B.Sc. M.D., Master’s Degree Business Chief Finance Officer Acting Chief Medical Officer Chief Technical Officer Chief Business Officer Chief Executive Officer ANDERS HÄRFSTRAN
Slide 5: 2020 – a year of delivering and transformation
2020 – a year of delivering and transformation Growing, with a clearly defined strategy 2021 onwards Maximizing Apealea® Opportunity to build a sustainable, profitable specialty pharma company Building the pipeline through in-house R&D, M&A, and in-licensing of clinical assets Focusing resources Sec
Slide 6: XR-17 – tackling poor drug solubility
XR-17TM – tackling poor drug solubility POOR API1 AFFECTS c.40% OF IMPLICATED IN SERIOUS A SIGNIFICANT PROBLEM FOR PATIENTS SOLUBILITY APPROVED DRUGS2 ADVERSE EVENTS AND PHARMA COMPANIES Major challenge in 70-90% of pipeline Solubility enhancers $180 bn SPENT ON drug development drugs classed as can
Slide 7: XR-17 – potentially improving safety and efficacy
XR-17™ – potentially improving safety and efficacy High drug delivery capability Cancers: Shorter infusion time1,2 Ovarian Superior solubility Prostate Enhanced API bioavailability Bladder Validated safety in cancer 1 Lung No or limited need for pre-medication1 Breast No alcohol, Crem. EL, Polys.80,
Slide 8: Building a portfolio, focused initially on cancer
Building a portfolio, focused initially on cancer Registration / Commercial Product Indication Pre-clinical Phase I Phase II Phase III approval Launch Geography Human Health Portfolio Apealea® / Ovarian cancer USA Paclical® (paclitaxel) Ovarian cancer EU / EEA Docetaxel Prostate cancer Global micell
Slide 9: Apealea – offering an improved treatment option in ovarian cancer
Apealea® – offering an improved treatment option in ovarian cancer Solvent-free IV formulation of paclitaxel • No polyoxyethylated castor oil or dehydrated alcohol • No glucocorticosteroids required pre- medication • Shorter infusion and overall ‘chair’ time Approved in EU for treatment of first rel
Slide 10: Apealea – global partnership worth up to $698m + royalties
Apealea® – global partnership worth up to $698m + royalties Agreement with US-based Elevar Therapeutics, subsidiary of South Korea’s HLB % Double digit royalties on global Apealea® sales Milestones based on regulatory and sales $678M achievements Oasmia retains sole control over development of XR-17
Slide 11: Apealea - global commercialization progressing well
Apealea® - global commercialization progressing well Nordic states Peak sales • Oasmia commercializing estimates ~$275m - $282m (ovarian Europe (excluding Nordics) cancer1) USA • Commercialization agreement signed • Pathway to commercialization identified between Elevar Therapeutics and and being ex
Slide 12: Docetaxel micellar – initiating phase 1b to target prostate cancer
Docetaxel micellar – initiating phase 1b to target prostate cancer • Docetaxel approved for wide 1 in 7 range of solid malignancies men will be diagnosed with • Standard of care for advanced prostate cancer prostate cancer • Docetaxel micellar uses XR-17™ to enable IV administration of docetaxel wit
Slide 13: Improving and expanding the use of our technologies
Improving and expanding the use of our technologies Project Objective Discovery Feasibility Development Validation Launch Solubilization platform XR-17™ Out licensing and sales Next generation of XR-18 XR-17 Target 2023 Out licensing and sales Solubilization platform XR-19 – dual encapsulation Targe
Slide 14: Focusing resources – strong cash position & reduced burn rate
Focusing resources – strong cash position & reduced burn rate 2019/20 2019 2020 May - Apr May - Jul May - Jul 435,000 109,000 354,000 Cash and Cash equivalents, TSEK* Number of shares at the end of the period, before 448,370 326,313 448,370 and after dilution, in thousands1 Weighted average number o
Slide 15: Looking ahead – multiple catalysts and investment drivers
Looking ahead – multiple catalysts and investment drivers Potential near and mid-term value drivers Investment drivers • Elevar partnering for Apealea® in key territories • Commercial-stage company with proven and milestone payments and royalties capabilities • SAKK docetaxel micellar Phase Ib initi
Slide 16: Our four-pillar strategy for growth
Our four-pillar strategy for growth 1 2 3 4 Execute on Partnering & clinical Clinical In / out-licensing, Apealea® global development with development of partnering & M&A partnership with XR-17™ / XR-19 Docetaxel micellar in oncology Elevar Therapeutics platforms and new API(s) 16
Slide 17: Thank you!
Thank you! Oasmia Pharmaceutical AB (STO: OASM) +46 018-50 54 40 www.linkedin.com/comp Vallongatan 1 any/oasmia- 752 28 Uppsala [email protected] pharmaceutical-ab Sweden www.oasmia.com www.twitter.com/Oasmia